Tevogen Inc. TVGN
At closeNov 3, 2026, 4:02 PM EST
After hours · Nov 3, 4:02 PM ET
- YTD
- -64.23%
- 1 year
- -79.86%
- Market cap
- 93.16M
- EPS (ttm)
- -6.74
- Shares out
- 175.05M
- YTD return
- -64.23%
- 1-year return
- -79.86%
- Volume
- 6.23K
- Avg volume
- 8.18K
- Open
- 5.51
- Previous close
- 5.59
- Day's range
- 5.51 – 5.97
- 52-week range
- 3.64 – 32.50
- Beta
- -1.03
- Price target
- 4.20 (-29.1%)
2Y -92.05 (-93.93%)
Key statistics
- Enterprise value
- 235.76M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 10.55M
- Total cash
- 1.14M
- Total debt
- 2.02M
- Return on equity
- 0.00%
- Short % of float
- 11.70%
- 50-day average
- 1.49
- 200-day average
- 1.37
Analyst view
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
About Tevogen Inc.
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tevogen.com
News
Tevogen Bio (NASDAQ:TVGN) Stock Falls 1.6% – Time to Sell? 
UPDATE – Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC 
Tevogen Signs Letter Of Intent To Evaluate A Potential Transaction With HRK Healthcare; Sees Path To Realizing ~$100M In Combined Annual Revenue 
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC 
Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements 
Tevogen To Operate Under Tevogen Inc. Name, Effective July 30 
Tevogen Bio Holdings Inc. Becomes Tevogen Inc. 
Tevogen Bio Announces 2026 Annual Meeting of Stockholders 
12 Health Care Stocks Moving In Monday's Pre-Market Session 
Tevogen Creates Healthcare Services Initiative Led By VP Of Strategic Initiatives William Keane On Interim Basis
Your note
Sign in to keep a note on TVGN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CORBIN CAPITAL PARTNERS, L.P. | Beneficial Owner of more than 10% of a Class of Security | Sale | Jul 16, 2023 | 0 |
| DESAI KIRTI | Chief Financial Officer | Purchase | Jun 11, 2024 | 9,699,190 |
| FEIKE JEFFREY L | Director | Stock Award(Grant) | Feb 13, 2024 | 581,771 |
| FLOMENBERG NEAL | Officer | Sale | Oct 16, 2024 | 4,254,300 |
| GOH KEOW LIN | Director | Stock Award(Grant) | Feb 13, 2024 | 193,923 |
| KHAN SADIQ | Officer | Stock Award(Grant) | Feb 13, 2024 | 969,618 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Portland Global Advisors Llc | 1.06% | 1,854,517 | 1.87M | Sep 29, 2024 |
| Polar Asset Management Partners Inc. | 0.90% | 1,577,387 | 1.59M | Sep 29, 2024 |
| Cantor Fitzgerald, L.P. | 0.34% | 603,691 | 609.73K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.20% | 344,285 | 347.73K | Sep 29, 2024 |
| Blackrock Inc. | 0.13% | 230,918 | 233.23K | Sep 29, 2024 |
| HGC Investment Management Inc. | 0.13% | 223,077 | 225.31K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Small Cap Index Fund | 0.12% | 207,166 | 209.24K | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.08% | 145,899 | 147.36K | Oct 30, 2024 |
| Vanguard Russell 2000 Index Fund | 0.05% | 88,044 | 88.92K | Aug 30, 2024 |
| iShares Micro Cap ETF | 0.04% | 63,239 | 63.87K | Oct 30, 2024 |
| Schwab Capital Trust-Small Cap Index Fund | 0.03% | 49,581 | 50.08K | Jul 30, 2024 |
| Fidelity Extended Market Index Fund | 0.03% | 57,911 | 58.49K | Oct 30, 2024 |